- Home
- CDMO vs LXRX Comparison
CDMO vs LXRX Comparison
Compare CDMO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDMO
- LXRX
- Stock Information
- Founded
- CDMO 1981
- LXRX 1995
- Country
- CDMO United States
- LXRX United States
- Employees
- CDMO N/A
- LXRX N/A
- Industry
- CDMO Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- CDMO Health Care
- LXRX Health Care
- Exchange
- CDMO Nasdaq
- LXRX Nasdaq
- Market Cap
- CDMO 784.1M
- LXRX 650.7M
- IPO Year
- CDMO N/A
- LXRX 2000
- Fundamental
- Price
- CDMO $12.15
- LXRX $0.98
- Analyst Decision
- CDMO Buy
- LXRX Buy
- Analyst Count
- CDMO 5
- LXRX 2
- Target Price
- CDMO $13.63
- LXRX $6.00
- AVG Volume (30 Days)
- CDMO 3.6M
- LXRX 4.3M
- Earning Date
- CDMO 12-05-2024
- LXRX 11-12-2024
- Dividend Yield
- CDMO N/A
- LXRX N/A
- EPS Growth
- CDMO N/A
- LXRX N/A
- EPS
- CDMO N/A
- LXRX N/A
- Revenue
- CDMO $142,358,000.00
- LXRX $5,229,000.00
- Revenue This Year
- CDMO $19.31
- LXRX $1,212.46
- Revenue Next Year
- CDMO $21.14
- LXRX $219.10
- P/E Ratio
- CDMO N/A
- LXRX N/A
- Revenue Growth
- CDMO N/A
- LXRX 886.60
- 52 Week Low
- CDMO $4.07
- LXRX $0.97
- 52 Week High
- CDMO $12.48
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- CDMO 67.73
- LXRX 25.78
- Support Level
- CDMO $11.67
- LXRX $1.01
- Resistance Level
- CDMO $12.30
- LXRX $1.35
- Average True Range (ATR)
- CDMO 0.27
- LXRX 0.12
- MACD
- CDMO 0.17
- LXRX -0.06
- Stochastic Oscillator
- CDMO 89.03
- LXRX 0.43
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.